Connect with us

Science

Penny Stocks With Huge Potential According To 4 Wall Street Analysts

Penny stocks with huge potential according to analysts in 2022.
The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared…

Published

on

Every retail trader wants to find penny stocks with huge potential. Thanks to the rise of the “Ape” movement, the opportunity in the market was presented during the early days of the pandemic. Weathered stocks like GameStop (NYSE: GME) or Bed Bath & Beyond (NASDAQ: BBBY) got their time in the sun as massive short squeezes triggered huge moves. While 2022 is a much different landscape than 2020 or 2021, retail traders remain on the hunt for penny stocks with huge potential. Today, we look at a few that analysts have high hopes for.

Penny Stocks With Huge Potential
[according to analysts]

Best Penny Stocks To Buy

Now, the critical part is figuring out the best penny stocks to buy. Since these cheap stocks can move hundreds of percentage points within minutes, a strategy is essential. This will also help determine “the best” based on your specific criteria. If you’re a swing trader, then a highly volatile penny stock might not be the best to buy. Then again, if you’re a day trader, stocks that take weeks to return gains aren’t the best for your trading style. At the end of this article, you can decide if you agree with four analysts on Wall Street with bullish outlooks on these penny stocks.

Better Therapeutics (NASDAQ: BTTX)

What Does Better Therapeutics Do?

Better Therapeutics bills itself as a “prescription digital therapeutics” company focused on nutritional, behavioral therapy. Its goal is to address the causes of cardiometabolic diseases in patients. According to the American College of Cardiology, “An estimated 47 million people in the U.S. are living with cardiometabolic disorders, putting them at an increased risk of developing heart disease or type 2 diabetes.”

BTTX Stock News

Shares of BTTX stock have heated up this week. That was thanks to growing interest around low float penny stocks among the FinTwit (Financial Twitter) crowd. With some outlets showing a public float of fewer than 10 million shares, BTTX stock met the criteria. Since then, things have become much more active, and daily trading volumes are higher than average.

Top Penny Stocks to Buy Today? Must-Knows For Trading on May 4th

BTTX Stock Forecast

What do analysts expect from BTTX stock? Earlier this year, Chardan Capital updated its outlook and maintained a Buy rating on the stock. The firm also boosted its $17 price target to $18, setting the bar high for Better Therapeutics. With trading levels around $2 right now, Chardan’s outlook implies a price 800% higher.

Alaunos Therapeutics Inc. (NASDAQ: TCRT)

What Does Alaunos Therapeutics Do?

Alaunos is a clinical-stage biotech company developing oncology-focused cell therapies. It has clinical and strategic collaborations with institutions like The University of Texas MD Anderson Cancer Center and the National Cancer Institute.

TCRT Stock News

Earlier this month, Alaunos announced that it dosed its first patient in its T-cell Receptor library Phase 1/2 trial for treating patients with solid tumors. Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos, said, “We believe that our adaptive trial design has the potential to allow us to rapidly and cost-effectively identify the recommended phase 2 dose and quickly advance studies in the most promising indications. We look forward to an initial data readout in the second half of this year.”

TCRT Stock Forecast

What do analysts think about TCRT stock? Wells Fargo is the most recent firm to weigh in on the penny stock. Analysts gave the penny stock an Overweight rating and announced a $3 price target. Based on the latest trading levels below $0.70, Wells Fargo’s target is more than 320% higher.

Sunworks Inc. (NASDAQ: SUNW)

What Does Sunworks Do?

Solar and alternative energy stocks had their hay day last year. But in 2022, things have been a bit different. Sunworks has experienced significant levels of volatility, especially in March. This was when oil prices surged higher and triggered a sympathy move in solar-related stocks. Sunworksprovides high-performance solar power systems to its customers, so there was a direct impact on SUNW stock earlier in the year.

SUNW Stock News

There’ve been a few news catalysts that have brought some attention to SUNW stock. First, the company launched its ESG (Environmental, Social, & Governance) reporting program last month. Sunworks have created a corporate responsibility committee to manage these ESG activities. The company said it plans on delivering “measurable, multi-year targets” to prioritize its sustainability efforts. In addition, for those with SUNW stock on their list this month, keep May 16th in mind. This is when Sunworks delivers its next round of earnings results.

SUNW Stock Forecast

Northland Capital Markets initiated coverage on SUNW stock this week. The firm has an Outperform rating and announced a $4.50 price target. Though it isn’t the highest expectation on this list of penny stocks, Northland’s target is still more than 136% higher than current trading levels.

Mind Medicine Inc. (NASDAQ: MNMD)

best penny stocks to watch mindmed MNMD stock

What Does Mind Medicine Do?

Psychedelic stocks are becoming a hot topic of discussion. Much like the early days of the cannabis boom, speculation has become a driving force more than fundamental analysis. MindMed is developing brain health treatments, including addiction, pain, and neurology.

MNMD Stock News

Last month MindMed announced plans for presenting topline clinical trial results for its LSD treatment for anxiety disorders. The details will be released next week at the PSYCH Symposium on May 11th.

3 Penny Stocks to Watch During the Stock Market Crash

MNMD Stock Forecast

Roth Capital analysts initiated coverage on MNMD stock this week. The firm gave MindMed a Buy rating and a $7 price target. Based on MNMD stock’s price below $0.90, that target is hefty. Those keeping track at home will find it to be over 670% higher.

Penny Stocks With Huge Potential According To Analysts

The general theme of this article is all about analysts. Are they always correct? Are they always incorrect? The answer to both of those questions is no. Since that is the case, it’s always essential to research and determine if current trends align with your outlook. If any of these are on your list of penny stocks right now, do you agree or disagree with analysts?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Vaccinia virus MacGyvers a makeshift tool to repair its DNA, exposing a vulnerability that could be targeted

Instead of relying on the cell’s repair mechanisms, the vaccinia virus MacGyvers a tool for DNA repair from one that it already uses to copy DNA, reports…

Published

on

Instead of relying on the cell’s repair mechanisms, the vaccinia virus MacGyvers a tool for DNA repair from one that it already uses to copy DNA, reports a team of researchers at the Medical University of South Carolina (MUSC) in the Journal of Virology. Blocking that tool – an enzyme known as polymerase – at once disrupts the virus’s ability to copy and to repair DNA, exposing an Achilles’ heel that could be targeted with a therapeutic. 

Credit: Medical University of South Carolina. Photo by Sarah Pack.

Instead of relying on the cell’s repair mechanisms, the vaccinia virus MacGyvers a tool for DNA repair from one that it already uses to copy DNA, reports a team of researchers at the Medical University of South Carolina (MUSC) in the Journal of Virology. Blocking that tool – an enzyme known as polymerase – at once disrupts the virus’s ability to copy and to repair DNA, exposing an Achilles’ heel that could be targeted with a therapeutic. 

“For vaccinia virus, polymerase is a Sawzall – a tool that you can use for everything” said Paula Traktman, Ph.D., senior author of the article and dean of the College of Graduate Studies at MUSC, who has studied the virus for decades. “Viruses have smaller chromosomes, and so they’ve evolved to be able to use their tools for different things.”

“It’s like the virus’s Swiss Army knife,” said Conor Templeton, Ph.D.  lead author of the article, who was a predoctoral candidate in the Traktman laboratory during the study and has since completed his doctorate. “It’s a protein that’s involved in replicating or copying DNA, but it also seems to be involved in repair.”

Such detailed basic science findings about the way viruses copy and repair their DNA have paved the way for breakthrough antiviral therapies in the past 20 years, said Traktman.

“HIV antiretroviral drugs were made by really painstaking analysis of which proteins in the virus are essential, leading to drugs that now have made it a chronic disease,” she said. “A curative treatment for hepatitis C was made possible by painstaking analysis of which proteins are essential for the virus. The more we know about the enemies, the better the weapons we can develop against them.”

Better therapies for pox viruses are certainly needed. The vaccinia virus is a close relative of the virus causing smallpox and was used in the vaccine that successfully eradicated it in the late 20th century. Although smallpox no longer naturally occurs, the threat that it might be used as a bioweapon remains, and currently, there is only one approved antiviral agent against it. Other pox viruses, most notably monkeypox, continue to afflict humans and can be lethal.

Vaccinia is a large DNA virus made up of about 200 genes, and its approach to survival differs markedly from that of smaller, nimbler RNA viruses, such as that which causes COVID-19. The RNA viruses mutate quickly to outrun the body’s immune system. However, they do so at the cost of corrupting their genome. Vaccinia virus prefers a slower, steadier approach and is less likely to make mistakes, helping to ensure genomic stability.

“Vaccinia has gone for ‘I may not be a Ferrari, but I’m a jeep, and I’m going to come out undamaged, and I’m going to be stable, and I’m going to stick around,’” said Traktman.

Unlike other DNA viruses, vaccinia virus does not set up shop in the cell’s nucleus but instead stays in the cytoplasm, where it begins reproducing itself using only the tools it brought with it.

“The nucleus is like the kitchen of the cell,” said Traktman. “If you came into somebody’s house to cook dinner, you would go to their kitchen because that’s where all the necessary equipment is. You wouldn’t decide to go downstairs to their basement because then you’d have to start from scratch. But that’s what vaccinia does. It says ‘I’m not going into the kitchen where you cook. I’m going to just set up shop in the basement, where there’s lots of space. I’ll build everything I need.’”

The MUSC team wanted to see how vaccinia virus would react to damage to its DNA caused by ultraviolet (UV) radiation. They chose UV radiation because it is already known to affect viral replication negatively. They also wanted to know whether exposing the cell to UV radiation one hour before infection with vaccinia would affect the virus’s ability to copy and repair DNA.

The MUSC team found that exposing cells to UV radiation either one hour before or four hours after infection with vaccinia virus reduced the number of mature viral units, or virions, vaccinia was able to produce.

The enzyme polymerase is known to be necessary for successful viral replication, and UV radiation can prevent it from doing its job.

“Polymerase is like a car running down the road,” said Templeton. “It runs smoothly when the road is nice and flat. But UV radiation acts like a speed bump, stopping it in its tracks.”

The UV radiation can cause damage that makes it impossible for DNA replication to continue.

The team found UV-caused damage in the viral DNA of cells irradiated four hours after infection but not in those irradiated an hour before infection. The cells irradiated at four hours after infection also produced 30 times fewer new viruses. This UV-caused damage could account for the reduced infectivity of these cells. Although viral DNA levels were able to recover slightly by 10 to 18 hours, suggesting some viral DNA repair, blocking polymerase resulted in a further tenfold to twentyfold reduction.

“Polymerase is a well-known character in DNA replication,” said Traktman. “It’s a well-known character in actually synthesizing the genome, but this is its debut in repair.”

In essence, the virus’s polymerase “multitasks,” but in so doing makes the virus vulnerable. Because vaccinia relies on polymerase both for DNA copying and repair, blocking it could be a particularly devastating weapon against the virus. The current blocking agent, however, is too broad, and a much more tailored one would be needed for the clinic.

Next, the MUSC team wants to understand better why blocking polymerase makes the DNA more vulnerable to damage and less able to repair itself.

“We want to establish the ensemble of culprits in that process and then try to understand why it is that when you inhibit polymerase function, you see this sensitivity,” said Templeton.

About MUSC

Founded in 1824 in Charleston, MUSC is home to the oldest medical school in the South as well as the state’s only integrated academic health sciences center, with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. MUSC brought in more than $327.6 million in biomedical research funds in fiscal year 2021, continuing to lead the state in obtaining federal and National Institutes of Health funding, with more than $220 million. For information on academic programs, visit musc.edu.

As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care available while training generations of compassionate, competent health care providers to serve the people of South Carolina and beyond. Patient care is provided at 14 hospitals with approximately 2,500 beds and five additional hospital locations in development, more than 300 telehealth sites and nearly 750 care locations situated in the Lowcountry, Midlands, Pee Dee and Upstate regions of South Carolina. In 2021, for the seventh consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

MUSC and its affiliates have collective annual budgets of $4.4 billion. The more than 24,000 MUSC team members include world-class faculty, physicians, specialty providers, scientists and care team members who deliver groundbreaking education, research, technology and patient care.


Read More

Continue Reading

Spread & Containment

World-first study reveals why people with COPD are more susceptible to COVID-19

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive…

Published

on

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.

Credit: Centenary Institute

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.

The findings, reported in the American Journal of Respiratory and Critical Care Medicine, could lead to the development of new therapeutic interventions that reduce COVID-19 infection in COPD patients.

An inflammatory lung condition, COPD causes airway blockage and makes it difficult to breathe. It affects around 400 million people globally. The increased susceptibility to COVID-19 of COPD patients is still to be fully understood.

In the study, the researchers infected differentiated airway cells from COPD patients and healthy people with SARS-CoV-2 (the virus that causes COVID-19).

The researchers found that the COPD airway cells had 24-fold greater infection with SARS-CoV-2 than the healthy cells.

“We examined the genetic information of infected cells through advanced single cell RNA-sequencing analysis,” said lead author of the study, Dr Matt Johansen, from the Centenary UTS Centre for Inflammation.

“Seven days after SARS-CoV-2 infection, there was a 24-fold increase of viral load in the COPD patient airway cells compared to the cells taken from healthy individuals.”

Significantly, the team found that the infected COPD cells had increased levels of transmembrane protease serine 2 (TMPRSS2) and cathepsin B (CTSB). Both are enzymes that SARS-CoV-2 uses to enter into the host cell.

“These two enzymes are increased in COPD patients and favour greater SARS-CoV-2 infection compared to healthy people. Simply put, easier and increased cell infection makes it far more likely that individuals with COPD will have more severe disease outcomes,” said Dr Johansen.

Other results from the study showed additional reasons for COPD patient susceptibility to severe COVID-19.

Key anti-viral proteins (interferons) that protect against infection were largely blunted in the COPD patient airway cells. This was a likely trigger in causing increased viral production in COPD patients.

Dr Johansen said that infected COPD patient airway cells also had higher levels of pro-inflammatory cytokines, which are linked to more severe COVID-19 and COPD outcomes.

“COPD is an inflammatory disease with patients having increased inflammation at baseline compared to healthy people. It’s highly likely that SARS-CoV-2 exacerbates this existing high inflammation level which leads to even poorer outcomes,” he said.

Initial laboratory drug testing by the researchers, to inhibit the enzymes TMPRSS2 and CTSB, and to target the high inflammation levels, successfully and substantially reduced SARS-CoV-2 viral levels in COPD patient cells, ultimately confirming the study’s results.

“Collectively, these findings have allowed us to understand the mechanisms of increased COVID-19 susceptibility in COPD patients,” said Professor Phil Hansbro, the study’s senior author and Director of the Centenary UTS Centre for Inflammation.

“We believe that new drug treatments targeting relevant enzymes and pro-inflammatory responses in SARS-CoV-2 infection could have excellent therapeutic potential in reducing the severity of COVID-19 in patients with COPD.”

Professor Hansbro said the research was critical with hundreds of millions of people affected by COPD globally and with COVID-19 likely to be around for many years to come.

[ENDS]

Publication:

Increased SARS-CoV-2 Infection, Protease and Inflammatory Responses in COPD Primary Bronchial Epithelial Cells Defined with Single Cell RNA-Sequencing.

https://www.atsjournals.org/doi/10.1164/rccm.202108-1901OC

Images:

Dr Matt Johansen: https://drive.google.com/file/d/1Wc5WxHcS1fSWE68Q7xu8jT53Dki2ZBo4/

 

Professor Phil Hansbro:

https://drive.google.com/file/d/1GaHOyCjXfSb3hsE_bS-g2Cxs81dEhL4G/

 

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: t.crawshaw@centenary.org.au

 

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research focuses on three key areas: cancer, inflammation and cardiovascular disease. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

For more information about the Centenary Institute, visit centenary.org.au

 

About the University of Technology Sydney (UTS)

The University of Technology Sydney (UTS), located in central Sydney, is one of

Australia’s leading universities of technology. It is known for fusing innovation, creativity

and technology in its teaching and research and for being an industry-focused university.

For more information go to uts.edu.au


Read More

Continue Reading

Government

The New Rift Between WHO And China

The New Rift Between WHO And China

Authored by Jeffrey Tucker via The Brownstone Institute,

From the beginning of the pandemic, the World…

Published

on

The New Rift Between WHO And China

Authored by Jeffrey Tucker via The Brownstone Institute,

From the beginning of the pandemic, the World Health Organization and China’s CCP have worked and spoken hand-in-glove, culminating in the Potemkin Village junket of mid-February 2020. The WHO-sponsored travel report—how wonderfully China had performed!—was written and signed by American public health officials who recommended Wuhan-style lockdowns, a disastrous policy that further inspired most governments in the world to do the same.

Twenty-six months later, it turns out that China in fact had not “eliminated the virus fully within its borders,” contrary to the over-the-top claims of TV pundit Devi Sridhar in her new book “Preventable.” They only pushed cases into the future, as the CCP discovered when positive tests appeared all over Shanghai, leading to 7 weeks of brutal lockdowns.

This move on China’s part has been a disaster for the country and the world economy, and presently endangers the financial and technological future of the entire country.

For Xi Jinping, lockdowns and zero-covid were his greatest achievement, one which was celebrated the world over, causing his political pride to swell beyond all bounds. Now, he cannot back off lest he face possible losses in upcoming party elections.

Just this past weekend, he made it clear to the entire government that there would be no backing off the zero-covid policy: the CCP will “unswervingly adhere to the general policy of ‘dynamic zero-Covid,’ and resolutely fight against any words and deeds that distort, doubt or deny our country’s epidemic prevention policies.”

The problem is acute: vast numbers in China likely need to acquire natural immunity via exposure. The lockdown policy likely puts a damper on the achievement of endemicity. That means long-term damage to China’s future.

Sensing this problem, the head of the WHO, Tedros Adhanom Ghebreyesus, offered a mild criticism:

“Considering the behavior of the virus, I think a shift will be very important,” adding that he had discussed this point with Chinese scientists.

What happened next is truly fascinating: Tedros’s comments were censored all over China and searches for the name Tedros were immediately blocked within the country.

Implausibly, merely by stating the incredibly obvious point, Tedros has made himself an enemy of the state.

Meanwhile, another WHO/China partisan, Bill Gates, has been sheepishly saying something very similar in interviews, namely that the virus cannot be eradicated.

It’s not just Tedros and Gates who are trying to flee their advocacy of lockdowns. Anthony Fauci himself denied that the United States ever had “complete lockdowns”—which is technically correct but not because he didn’t demand them.

On March 16, 2020, Fauci faced the national press and read from a CDC directive: “In states with evidence of community transmission, bars, restaurants, food courts, gyms and other indoor and outdoor venues where groups of people congregate should be closed.”

In fact, one gets the strong sense that governments around the world are pretending as if the whole pathetic and terrible affair never happened, even as they are attempting to reserve the power to do it all over again should the need arise.

On May 12, 2022, many governments around the world gathered for a video call and agreed to pour many billions more into covid work, and reaffirm their dedication to an “all-of-society” and “whole-of-government” approach to infectious disease. The U.S. government under the administration readily agreed to this idea.

Leaders reinforced the value of whole-of-government and whole-of-society approaches to bring the acute phase of COVID-19 to an end, and the importance of being prepared for future pandemic threats. The Summit was focused on preventing complacency, recognizing the pandemic is not over; protecting the most vulnerable, including the elderly, immunocompromised people, and frontline and health workers; and preventing future health crises, recognizing now is the time to secure political and financial commitment for pandemic preparedness.

The Summit catalyzed bold commitments. Financially, leaders committed to provide nearly $2 billion in new funding—additional to pledges made earlier in 2022. These funds will accelerate access to vaccinations, testing, and treatments, and they will contribute to a new pandemic preparedness and global health security fund housed at the World Bank.

Is it progress to see these people throwing around language from the much-criticized but now wholly vindicated Great Barrington Declaration? Doubtful. You can’t make a bad policy better by tossing around words. There is every indication from this statement that there will be no apologies, no regrets, and no changes in the default position that governments must always and everywhere have maximum power to control any pathogen of their choosing.

Despite Tedros’s censored words, it’s no wonder that Xi Jinping continues to feel vindicated and affirmed, and sees no real political danger in choosing his own power over the health and well-being of his people. Governments around the world still cannot muster the courage to make a full-throated and solid attack on zero-covid, for fear of the implications of such a concession. Nudges and hints, even from the WHO, will not do it.

Tyler Durden Mon, 05/16/2022 - 19:45

Read More

Continue Reading

Trending